NEWS AND RESOURCES

Mouse Models for Studying Anti-PD-1 Resistance

Immune checkpoint inhibitors targeting PD-1/PD-L1 have revolutionized cancer treatment, offering broad-spectrum efficacy, prolonged durability, and relatively low toxicity[1]. Despite these advancements, the response rates in many cancers remain disappointing, often below 30%[2]. A significant proportion of patients experience partial responses or worse — eventually developing resistance leading to disease progression. These challenges highlight the urgent need for developing novel therapies to overcome anti-PD-1 resistance. This blog will explore how GemPharmatech has developed its own models of anti-PD-1 resistance.